Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Sep. 30, 2020

Quarterly Financial Information Disclosure [Abstract]


	Fiscal Year Ended September 30, 2020
(in thousands, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Fiscal Year
Revenue	$	47,864,742	$	47,417,639	$	45,366,777	$	49,244,768	$	189,893,926
Gross profit (a)	$	1,231,214	$	1,388,107	$	1,225,716	$	1,346,847	$	5,191,884
Distribution, selling, and administrative expenses; depreciation; and amortization	790,468		787,208		762,300		818,303		3,158,279
Employee severance, litigation, and other (b)	39,309		67,732		58,585		6,641,681		6,807,307
Impairment of PharMEDium assets	138,000		223,652		—		—		361,652
Operating income (loss)	$	263,437	$	309,515	$	404,831	$	(6,113,137)	$	(5,135,354)
Net income (loss) (c)	$	186,568	$	971,111	$	287,268	$	(4,844,505)	$	(3,399,558)
Net income (loss) attributable to AmerisourceBergen Corporation (c)	$	187,640	$	960,277	$	289,439	$	(4,846,072)	$	(3,408,716)
Earnings per share operations:
Basic	$	0.91	$	4.68	$	1.42	$	(23.74)	$	(16.65)
Diluted	$	0.90	$	4.64	$	1.41	$	(23.74)	$	(16.65)

__________________________________________________________

(a)The first, second, and fourth quarters of the fiscal year ended September 30, 2020 include gains from antitrust litigation settlements of $8.5 million, $0.1 million, and $0.5 million, respectively. The first, second, and third quarters of the fiscal year ended September 30, 2020 include LIFO expense of $13.3 million, $23.9 million, and $6.1 million. The fourth quarter of the fiscal year ended September 30, 2020 includes LIFO credit of $35.8 million. The first quarter of the fiscal year ended September 30, 2020 includes PharMEDium remediation costs of $7.1 million. The second and third quarters of the fiscal year ended September 30, 2020 include PharMEDium shutdown costs of $5.0 million and $0.4 million, respectively.

(b)The fourth quarter of the fiscal year ended September 30, 2020 includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.

(c)The second quarter of the fiscal year ended September 30, 2020 includes discrete tax benefits of $741.0 million primarily related to the permanent shutdown of the PharMEDium business. The third quarter of the fiscal year ended September 30, 2020 includes a loss on the early retirement of debt of $22.2 million. The fourth quarter of the fiscal year ended September 30, 2020 includes tax benefits of $1.1 billion relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, $360.7 million relating to Switzerland tax reform, and a $20.4 million adjustment to the discrete tax benefits previously recognized primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business.


	Fiscal Year Ended September 30, 2019
(in thousands, except per share amounts)	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Fiscal Year
Revenue	$	45,392,452	$	43,319,602	$	45,239,265	$	45,637,802	$	179,589,121
Gross profit (a)	$	1,297,580	$	1,424,756	$	1,231,239	$	1,184,737	$	5,138,312
Distribution, selling, and administrative expenses; depreciation; and amortization	779,085		751,802		764,539		830,489		3,125,915
Employee severance, litigation, and other	40,672		55,389		60,006		174,407		330,474
Impairment of PharMEDium assets	—		570,000		—		—		570,000
Operating income	$	477,823	$	47,565	$	406,694	$	179,841	$	1,111,923
Net income (b)	$	391,753	$	28,073	$	302,002	$	132,307	$	854,135
Net income attributable to AmerisourceBergen Corporation (b)	$	393,652	$	27,135	$	301,959	$	132,619	$	855,365
Earnings per share operations:
Basic	$	1.86	$	0.13	$	1.44	$	0.64	$	4.07
Diluted	$	1.84	$	0.13	$	1.43	$	0.63	$	4.04

__________________________________________________________

(a)The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include gains from antitrust litigation settlements of $87.3 million, $52.0 million, $3.5 million, and $3.1 million, respectively. The first, second, and third quarters of the fiscal year ended September 30, 2019 include LIFO credits of $3.0 million, $66.8 million, and $9.9 million, respectively. The fourth quarter of the fiscal year ended September 30, 2019 includes LIFO expense of $57.2 million. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of $17.9 million, $12.3 million, $11.7 million, and $6.7 million, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a $22.0 million reversal of a previous estimate of a liability under the New York State Opioid Stewardship Act.

(b)The first quarter of the fiscal year ended September 30, 2019 includes a $37.0 million income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of $13.7 million.